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Background: The commonest genetic form of juvenile or early adult onset macular degeneration is Stargardt
Disease (STGD) caused by recessive mutations in the gene ABCA4. However, high phenotypic and allelic
heterogeneity and a small but non-trivial amount of locus heterogeneity currently impede conclusive molecular
diagnosis in a significant proportion of cases.
Methods: We performed whole exome sequencing (WES) of nine putative Stargardt Disease probands and
searched for potentially disease-causing genetic variants in previously identified retinal or macular dystrophy genes.
Follow-up dideoxy sequencing was performed for confirmation and to screen for mutations in an additional set of
affected individuals lacking a definitive molecular diagnosis.
Results: Whole exome sequencing revealed seven likely disease-causing variants across four genes, providing a
confident genetic diagnosis in six previously uncharacterized participants. We identified four previously missed
mutations in ABCA4 across three individuals. Likely disease-causing mutations in RDS/PRPH2, ELOVL, and CRB1 were
also identified.
Conclusions: Our findings highlight the enormous potential of whole exome sequencing in Stargardt Disease
molecular diagnosis and research. WES adequately assayed all coding sequences and canonical splice sites of ABCA4
in this study. Additionally, WES enables the identification of disease-related alleles in other genes. This work
highlights the importance of collecting parental genetic material for WES testing as the current knowledge of
human genome variation limits the determination of causality between identified variants and disease. While larger
sample sizes are required to establish the precision and accuracy of this type of testing, this study supports WES for
inherited early onset macular degeneration disorders as an alternative to standard mutation screening techniques.
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PRPH2Background
Individuals with early-onset macular degeneration (MD)
represent a diagnostic challenge. While observation of
MD in a juvenile or young adult strongly implies an
underlying genetic cause of disease, the spectrum of po-
tential genes and mutations known to cause MD is ex-
tensive. Given the variability of clinical features that
have been attributed to autosomal recessive mutations
in the ABCA4 gene [1-3], the most common clinical* Correspondence: strom@jsei.ucla.edu
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reproduction in any medium, provided the ordiagnosis for MD is Stargardt Disease [OMIM: #248200/
#600110] (STGD). Rare cases of STGD or “Stargardt-
like” disease phenotypes have been reported with muta-
tions in PRPH2 [4,5], VMD2 [6], ELOVL4 [7-9] and
PROM1 [10]. These genes, as well as ABCA4, are also
associated with clinically distinct phenotypes including
retinitis pigmentosa, cone/rod dystrophy and pattern
dystrophy. This complex arena of genes and clinical fea-
tures complicates the nomenclature in this field; it is un-
clear how to classify individuals with classic Stargardt
phenotype lacking recessive mutations in ABCA4. While
we do not limit the term “retinitis pigmentosa” to a
phenotype caused by mutations in a single gene, theretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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those cases caused by ABCA4 mutations and “Stargardt-
like” or juvenile macular dystrophy should be used for
other genetic etiologies. For the purposes of this study,
we classify our participants with early-onset macular de-
generation as “putative Stargardt Disease” cases.
Since the initial identification of recessive mutations in
the ABCA4 gene in several large STGD pedigrees [3], a
multitude of studies have attempted to assess the muta-
tional spectrum of ABCA4 in various ethnically
restricted populations (Italy [11,12]; Spain [13,14]; Japan
[15]; Portugal [16]; Hungary [17]; Denmark [18]). While
each population appears to carry some founder muta-
tions accounting for a significant proportion of disease
alleles, hundreds of extremely rare or private variants
have also been identified [19]. This allelic heterogeneity
hampers the viability of standard panel-based mutation
screening techniques and has lead to the creation of an
ABCA4 array designed to genotype over 600 individual
DNA variants [19]. While this array is an effective
screening tool, the high rate of private mutations in
STGD prevents it from being a comprehensive solution.
Another factor making ABCA4 such a difficult diag-
nostic target is its genomic structure. The large number
of coding exons in ABCA4 gene (50 coding exons result-
ing in a 6.8 kb mRNA [Refseq NM_000350]) makes
PCR-based sequencing costly and time-consuming. Cur-
rently, the cost of PCR and dideoxy-based targeted
ABCA4 exon sequencing is approximately half that of
WES. The costs of data analysis are difficult to compare,
but WES analysis is highly automatable and can be per-
formed in parallel as opposed to the highly labor-
intensive analysis required to identify rare variants from
individual sequence traces. Approaches using targeted
next-generation sequencing hold great potential for
ABCA4 mutation screening [20,21], and may reduce the
cost of single gene sequencing significantly.
Using a combination of methods to screen for ABCA4
mutations in 121 patients from a heterogeneous patient
population in our natural history study of Stargardt Dis-
ease, only half (59/121, 49%) of the cases were found to
have two known or putative disease-causing ABCA4
mutations on separate alleles. Nearly one third have a
single mutation, and the remaining ~20% have no defin-
ite or probable disease-causing ABCA4 mutations
(manuscript in preparation). Highly sensitive next-
generation targeted re-sequencing of ABCA4 has been
implemented on an independent sample set with similar
results [20]. Whether individuals with putative Stargardt
Disease with one or zero detected ABCA4 mutations
have non-traditional variation (e.g. promoter variants or
epigenetic changes) missed by current mutation screen-
ing techniques or mutations in other genes is unclear at
this time.Providing a genetic diagnosis for individuals with puta-
tive Stargardt Disease is thus an ongoing challenge. Here
we apply whole exome sequencing to nine putative
STGD cases to assess the efficacy of this approach for
molecular genetic diagnosis of this condition. All
patients were previously screened and found to have
zero (eight samples) or one (one sample) disease-causing
mutation in ABCA4. While some of these probands ex-
press ocular imaging phenotypes not typically observed
in classic STGD, all were diagnosed clinically as having
STGD due to the early age at which signs of macular de-
generation were initially identified.
In this study, we use the same WES methods and ana-
lytical tools as those implemented by laboratories now
offering CLIA-approved, clinical WES. As such, we re-
port these research findings as a preliminary surrogate




Participant samples were recruited into this study under
approval of the UCLA Institutional Review Board and
consented prior to participation. Each was diagnosed by
a referring retinal specialist and confirmed by a retinal
expert at the Jules Stein Eye Institute, University of Cali-
fornia Los Angeles (Gorin M.B) [22]. All research was
conducted in accordance with the Health Insurance
Portability and Accountability Act of 1996. A basic
ophthalmologic exam, electroretinogram (ERG), optical
coherence tomography (OCT) and imaging of the fun-
dus was performed for each individual. Clinical pheno-
typing summaries can be found in Table 1. Subjects
were selected for WES if they had an initial clinical diag-
nosis of Stargardt Disease and lacked mutations in
ABCA4 as screened by targeted dideoxy re-sequencing.
One case, STGD-02, was included as a positive control
having had one ABCA4 mutation detected previously by
Sanger sequencing.
Whole Exome Sequencing Data Generation
Randomly fragmented genomic DNA libraries were cre-
ated following standard protocols for high-throughput
paired-end sequencing on the Illumina GA2x or
HiSeq2000 instruments (Illumina Inc., San Diego, CA).
The Agilent SureSelect 50 Mb capture kit was used to en-
rich the libraries for known coding loci in the human gen-
ome (Agilent Technologies; Santa Clara, CA). This kit has
been shown to effectively capture >90% of these loci when
an adequate average read depth is reached [23].
Data Analysis
Nucleotide base calling and quality score assessment
was performed using instrument-specific Real Time
Table 1 Clinical Information and Genetic Findings of Putative Stargardt Disease Cases
Sample Age Sex Acuity OD
Acuity OS

















STGD-02 15 Female 20/160
20/100







STGD-03 58 Female 20/50
20/16
No significant atrophy Abnormal rod
Abnormal cone
No testing . p.W25C
p.Q276X
.






Abnormal . p.G167S .






Normal . p.T236X .
STGD-06 34 Female 20/200
20/200
Classic Stargardt Normal rod
Abnormal cone
No testing p.V989A . .






No testing . . .
STGD-08 37 Male 20/40
20/400
No peripapillary sparing/flecks;
irregular geographic atrophy with
RPE changes; thickening on OCT
Normal rod
Normal cone
Abnormal . . CRB1
p.K801X
STGD-09 61 Male 20/25
20/25
"Horseshoe" pattern of atrophy Normal rod
Normal cone
No testing . . ELOVL4
p.A311T
“Age” is age at ascertainment. Abbreviations: ERG - Electroretinogram; RPE - Retinal pigment epithelium; OD - right eye; OS - left eye. * Variant previously
observed by dideoxy sequencing. “Variants” indicates putatively causal variants and does not include predicted benign or common (polymorphic) variants.
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bination of commercially or academically available tools
and custom scripts were used to analyze the raw DNA
sequence reads. Alignment to the human genome (hg19;
NCBI build 37; Feb. 2009) was performed using Novoa-
lign (Novocraft Technologies; Selangor, Malaysia). Mer-
ging, sorting, and other manipulation of aligned data
was performed using SAMTools [24]. PCR clonal dupli-
cate removal was performed using Picard [http://picard.
sourceforge.net]. Quality score recalibration, genotyping,
variant filtration, and coverage depth analysis were per-
formed using the Genome Analysis Toolkit [25]. Variant
consequence analysis was performed using SeattleSeq
[26] which incorporates many databases including:
“NCBI full genes”, dbSNP131, and the 1000 Genomes
Project. Further analysis was performed using a combin-
ation of custom PERL scripts and Mathematica 7.0
(Wolfram Research; Champaign, IL).
Novel variants identified as putatively causal were
screened for presence in the NHLBI Exome Sequencing
Project database. Alleles present at ≥1% allele frequency
in either sample population (European Caucasian or Af-
rican American) were considered common alleles un-
likely to contribute to rare disease, and thus removed
from analysis.
Additional Sequencing
Targeted amplification of PRPH2 and ELOVL4 coding
sequences was performed using PCR (primer sequences
available in Additional file 1 Supplemental Materials).PCR products were then sent out for dideoxy sequencing
(Beckman Coulter; Brea, CA) and analyzed using Sequencher
software (Gene Codes Corp.; Ann Arbor, MI).
Results
Exome sequencing completeness and quality
All libraries were successfully sequenced with a mini-
mum mean on-target coverage depth of 44x (Additional
file 2 Table S1). Samples sequenced on the Illumina
HiSeq2000 had significantly higher coverage (average of
103x-121x) due to the increased volume of sequence
reads produced by this instrument compared to the
GA2x. Samples contained on average approximately
156,000 DNA variants from hg19, the vast majority of
which overlap a known polymorphism (Additional file 2
Table S1). The two individuals of African American des-
cent had an increased proportion of novel variants, con-
sistent with the higher levels of genetic heterogeneity in
that sub-population. Both the total number of variants
and proportion of which overlap a known polymorphism
were tightly correlated with read depth and are within
the expected limits based on other studies [23].
Whole exome sequencing using the Agilent SureSelect
50 Mb capture kit provided high quality base calls for a
minimum of 97.5% of the 6,822 base pair positions cor-
responding the translated ABCA4 mRNA. For samples
sequenced on the HiSeq2000 were covered, 100% of
bases were covered ≥8x (Additional file 2 Table S1). Ca-
nonical splice acceptor and splice donor sites were cap-
tured at a similar rate.
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Clinical summaries, including visual acuity, age of re-
cruitment, gender, ethnicity, and relevant ophthalmo-
logical findings are found in Table 1.
STGD-01
This participant exhibited several classic features of
STGD (Table 1, Additional file 3 Figure S1). Panretinal
cone dysfunction with preserved rod function was docu-
mented by ERG. Exome sequencing identified two mis-
sense variants (p.N965S and p.R2038W) previously
reported as disease-causing in STGD [19].
STGD-02
This participant presented with atypical macular degen-
eration (Table 1, Additional file 4 Figure S2). Two rare
coding variants in ABCA4 were identified by exome se-
quencing in this participant. The p.G1961E missense
variant is a known STGD mutation [19]. This variant
was previously detected by PCR amplification and
dideoxy sequencing and served as a positive control in
this study. The second variant p.Q636X introduces a
premature termination codon and is thus considered
very likely deleterious.
STGD-03
This participant was documented to have central vision
loss, more severe in the left eye (Table 1, Additional file
5 Figure S3a-S3b). Subretinal fluid was observed by
OCT (Additional file 5 Figure S3b-S3c). Multifocal ERG
showed near complete loss of the foveal peaks and uni-
formly reduced and delayed cone responses for the en-
tire testing areas of both eyes. Two rare, novel coding
variants in PRPH2 (p.W25C and p.Q276X) were identi-
fied in this participant. As parental genetic material is
not available and these two variants are non-adjacent, it
is not possible to assess phase. The missense variant is
predicted to be deleterious by all three algorithms imple-
mented by Condel [27]and the nonsense variant is
assumed to be deleterious.
STGD-04
This participant presented with bilateral symptoms in-
cluding central vision distortion, light/dark adaption dif-
ficulty, and intermittent photopsias. Clinical findings
were consistent with a pattern dystrophy (Table 1, Add-
itional file 6 Figure S4). Full field and multifocal ERGs
detected abnormal cone and rod amplitudes and implicit
times. Color vision (FM100 Hue) was bilaterally abnor-
mal, with greater severity for the left eye. A single rare
coding variant in PRPH2 was identified in this partici-
pant. This variant, p.G167S, has previously been linked
to pattern dystrophy [28] and is predicted to be deleteri-
ous by Condel. The participant’s father’s vision becameuncorrectable in the sixth decade of life, potentially con-
sistent with a dominant mode of inheritance.STGD-05
This participant showed signs of pattern dystrophy
(Table 1, Additional file 7 Figure S5). A single rare non-
sense variant (p.T236X) in PRPH2 was identified in this
participant. This variant has not been previously
described, but is likely deleterious as it introduces a pre-
mature termination codon. The proband’s father and pa-
ternal grandfather suffered from night blindness but, by
history, the visual impairment was not as severe as that
of the proband.STGD-06
This participant had classic features of STGD (Table 1,
Additional file 8 Figure S6). The full field ERG showed
abnormal cone responses with preserved rod function.
Exome sequencing identified a single, previously
described rare missense disease-causing variant in
ABCA4 (p.V989A). No other mutations were observed
in any of the other genes known to cause retinal or
macular dystrophies.STGD-07
This participant had several classical STGD features in-
cluding fundus flecks (Table 1, Additional file 9 Figure
S7). The full field ERG showed abnormal cone responses
with normal rod function. No clear candidate variants
were found by exome sequencing in any of the known
retinal or macular genes that might account for these
clinical findings.STGD-08
This participant was diagnosed with macular degener-
ation by age 16, but did not suffer from severe vision im-
pairment until age 37. No fundus flecks were observable,
though there was an irregular pattern of atrophy and
RPE changes (Table 1, Additional file 10 Figure S8a-
S8b). The central vision was impaired severely in the left
eye but less so in the right. The optical coherence tom-
ography study showed a diffuse thickening and loss of
lamination of the central retina without the presence of
cavitations or subretinal fluid (Additional file 10 Figure
S8b-S8c). The retinal appearance, while atypical for
patients with known Stargardt Disease, is similar to that
seen in retinal dystrophies attributable to CRB1 [29]. A
novel nonsense mutation p.K801X in the developmental
gene CRB1 was found by exome sequencing. There is no
family history of visual problems suggestive of a domin-
ant mode of inheritance.
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This participant presented with central vision loss and
geographic atrophy in a perifoveal “horseshoe” pattern
(Table 1, Additional file 11 Figure S9). Exome sequencing
identified a novel missense variant in ELOVL4: p.A311T.
An unconfirmed family history report indicated that his
father may have had similar visual impairment.
Additional PHPR2 and ELOVL4 sequencing
Direct re-sequencing of 68 additional putative Stargardt
Disease cases identified five individuals with either of
two previously reported PRPH2 mutations (p.P210R [30]
or p.172 W [5]). In total, rare coding variants in eight
out of 77 (10.4%) putative STGD cases from six inde-
pendent pedigrees were identified. This sample set is
enriched for patients without two known ABCA4 muta-
tions, suggesting this pickup rate is likely elevated com-
pared to the general STGD patient population. No
additional individuals were found to harbor putative
disease-causing variants in ELOVL4.
All eight individuals with at least one putatively dele-
terious PRPH2 allele were over the age of 50 at ascer-
tainment (age range 53–70 years). Two of these
individuals also carry at least one disease mutation in
ABCA4 identified by direct sequencing. Three had se-
vere atrophy, precluding the clinical observation of pat-
tern dystrophy that may or may not have been present
earlier in life. Among the five remaining cases, a clear
pattern dystrophy can be appreciated in only four out of
a possible ten maculae.
Discussion
The most common cause of early-onset macular degen-
eration is Stargardt Disease (STGD). Even in the context
of STGD - which is primarily caused by compound het-
erozygous missense, nonsense and/or splicing variants in
ABCA4 - there are key complicating factors that lead to
problems in precise molecular diagnosis. In this study
we examine the feasibility of performing whole exome
sequencing on putative STGD cases as either a supple-
ment or replacement for ABCA4-specific targeted meth-
odologies. To do this, we sequenced genomic DNA from
nine individuals with negative or unclear molecular diag-
nosis following direct sequencing of the major STGD
disease gene ABCA4. The sample size of this study limits
the determination of the general validity of this ap-
proach, but our results strongly suggest that mutation
detection of STGD patients by WES is highly effective as
compared to other methods.
Four out of five ABCA4 mutations were not detected
by PCR/dideoxy based exon sequencing and yet were
detected in the context of whole exome sequencing in
this study. Of the five total disease-causing ABCA4
alleles found by WES, four (all except p.Q636X) havepreviously been described and are genotyped by the
current ABCR array available from Asper Biotech, sup-
porting the use of the genotyping array as a first-pass
screening tool due to its low cost.
Two of these mutations were clearly visible as hetero-
zygous variants upon re-analysis of the original sequen-
cing traces. One of the newly identified mutations is
visible on the original sequence chromatogram but is
located within the first five bases of the read and thus
indistinguishable from normal background noise. The
chromatogram corresponding to the remaining variant
had a high level of noise throughout. Other laboratories
have noted similarly missed variants [31]. While cur-
rently considered the “gold standard” for molecular gen-
etic diagnosis of SNV-type mutations, PCR-based
dideoxy sequencing relies heavily on manual sequence
trace inspection and is thus subject to human error. This
method should and will continue to be relied upon for
many applications, including mutation validation and
genotyping of known alleles. However, it is difficult for a
molecular diagnostic laboratory to maintain a high level
of surveillance quality when performing a large number
of these assays, as is required for mutation screening in
STGD and other macular dystrophies.
Variant detection by exome sequencing is by compari-
son far more automated and less susceptible to this type
of error. The sources of error in WES are systematic and
readily measured. The major sources of erroneous find-
ings by WES are insufficient or uneven read depth
(“coverage”), mismapping, and incorrect variant annota-
tion. While these sources of error are complex to re-
solve, they are highly consistent which has allowed
computational advancements to dramatically improve
results. In contrast, the confounding issues facing capil-
lary gel electrophoresis-based dideoxy sequencing have
remained relatively stable since the inception of this
method. Our data supports the contention that WES
provides reliable and efficient mutation detection for
SNVs and indels in ABCA4, and is an attractive alterna-
tive to other methods.
Surprisingly, RDS/PRPH2 mutations were identified by
exome-seq in three individuals. This gene has been
linked to several other retinopathies including pattern
macular dystrophy [30,32-36] and retinitis pigmentosa
[37], and it has been previously suggested that mutations
in PRPH2 can mimic the STGD phenotype [38] or mod-
ify disease severity [5]. However, PRPH2 has not been
considered a significant contributor to classic STGD. In-
deed, two of the individuals carrying a heterozygous
PRPH2 mutation show a “stellate” pattern dystrophy in
one eye. While this is consistent with previous reports of
PRPH2-related disease [4,28,37-40], it is too subtle a
finding to confidently sub-classify patients. The lack of
concordance between two eyes of the same individual in
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file 7 Figure S5) suggests incomplete expressivity of this
endophenotype, suggesting that some cases with PRPH2
related disease may show no identifiable signs of pattern
dystrophy.
Additional mutations were detected by direct re-
sequencing of PRPH2 in a broader cohort of STGD
cases. Complicating matters, two out of the eight people
with rare missense or nonsense mutations in PRPH2 also
have mutations in ABCA4. One of these participants, a
compound heterozygote for ABCA4 mutations has two
affected relatives who share the PRPH2 mutations but
neither of the ABCA4 mutations. For these relatives, the
PRPH2 mutation appears to be disease-causing. In the
proband with a single ABCA4 mutation and a PRPH2
mutation, the genetic etiology of the disease is less clear.
At this time, it is not possible to assess the effect of this
potentially digenic scenario, though it has been previ-
ously observed [5]. The presence of rare, coding PRPH2
variants in STGD cases with one or more ABCA4 muta-
tions suggests that one must be cautious regarding at-
tributing apparent cases of Stargardt Disease to ABCA4
mutations when only ABCA4 has been screened.
Though rare, these cases support the implementation of
exome sequencing to detect potentially confounding
genetic mutations as well as enable the study of the ef-
fect of multi-gene mutation combinations on disease
progression and severity.
Mutations in CRB1 have been associated with a wide
array of retinal dystrophies, including retinitis pigment-
osa and Leber congenital amaurosis [41]. Here we report
the first finding of a heterozygous nonsense mutation in
CRB1 in an individual with macular degeneration. Given
that CRB1 is involved in normal retinal development,
this variant is an intriguing functional candidate. A
thickening of the fovea (without the cavitations asso-
ciated with macular edema) observable by OCT in this
participant is consistent with other cases of CRB1-
related disease. In the absence of a functional validation
of the p.K801X variant or analysis of additional cases
with nonsense variants in CRB1, it is not possible at
present to confidently assign a molecular diagnosis to
this case and we thus categorize this variant as being of
unknown significance. This inability to causally link a
suspect variant with phenotype is a significant limitation
of the technique, and will likely be typical of early clin-
ical WES efforts.
While it is attractive to attempt to correlate clinical
and phenotypic information with our newly acquired
genetic data, sample size is a significant limitation. For
example, one might hypothesize that individuals with
PRPH2 dysfunction would have abnormal cone/rod
responses due to its restricted expression to the outer
disc segment of photoreceptors [42]. However, given therange of variability across Stargardt cases and the small
number of PRPH2 positive cases, it is not possible to as-
sess any such correlation at present. Collaboration and
data sharing amongst multiple STGD research groups is
needed to sufficiently increase the sample size to evalu-
ate any genotype-phenotype correlations.
In this study, we suffer from the unavailability of
complete family history information and genetic material
from related individuals, particularly for participants
with variants outside of ABCA4. These limitations are
common in clinical practice. While both history and
DNA would provide critical insight into mode of inherit-
ance and shed light on the functional consequences of
observed genetic variants, we identified a clear molecu-
lar basis of disease in six out of nine cases.
Despite near total coverage of most genes, including
both ABCA4 and PRPH2 in all nine cases, several of our
cases elude a definitive molecular diagnosis. One case
has only a single ABCA4 mutation, one has a variant of
unknown significance in CBR1 and one sample has no
demonstrable mutations in any gene with known associ-
ation to retinal or macular degeneration. Careful manual
inspection of genes carrying potential compound hetero-
zygous, homozygous, and protein-truncating variants in
these individuals did not yield any strong functional can-
didates for novel STGD disease genes. It is now gener-
ally accepted that every individual carries a significant
burden of potentially pathogenic DNA variants within
the known exome [43], and STGD cases are no different
in this regard. Which, if any, such variants in genes not
currently associated with retinopathy in our sample con-
tribute to disease onset and progression cannot be
assessed at this time, nor can we rigorously address the
potential of other genetic variants acting in a dominant
fashion or in a digenic manner. The exome data pro-
vides an opportunity to make a concerted effort to re-
analyze these data as new disease genes and genetic
modifiers are implicated in retinal and macular dystro-
phies. In the meantime, several of our cases elude mo-
lecular diagnosis. While such cases represent a small
proportion of the overall STGD participant population,
they may eventually provide invaluable insight into the
pathogenesis of STGD and the biology of the retina.
The disease phenotype of STGD can be quite variable,
even amongst individuals carrying identical or putatively
similar ABCA4 mutations. Age of onset, electroretino-
gram response, disease progression and disease severity
are all clinically relevant parameters of phenotypic
variability in these participants. While some genotype-
phenotype correlations have been found for population-
specific ABCA4 mutations [11], the majority of this vari-
ability remains unexplained. One major benefit of exome
sequencing over targeted ABCA4 mutation screening is
the potential for identifying disease-modifying alleles in
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quencing can enable such studies as a byproduct of pro-
viding highly sensitive molecular testing.
Knowledge of genome-wide functional variation may
be particularly critical to enrollment of participants in fu-
ture clinical trials. Restoration or replacement of ABCA4
protein function would likely be insufficient for a partici-
pant harboring disease-causing mutations in additional
genes, such as seen with PRPH2 in this study. Thus the
positive identification of two mutations in ABCA4 may
not be a proper endpoint for molecular diagnosis in
STGD. In contrast, exome sequencing can help place
STGD participants into genomic context as it identifies
both common and rare functional genetic variation.
Clinicians now have a multitude of options available to
them for STGD mutation screening. Targeted approaches
continue to grow in sensitivity and shrink in cost [20], but
they will always be fundamentally limited to specific genes
or alleles. From these small-scale results, we find very
strong potential for STGD molecular diagnosis by exome
sequencing. Presently, an approach following up array-
based ABCA4 mutation screening with exome sequencing
is a prudent and cost-effective alternative to direct re-se-
quencing. In the near future, exome sequencing and in-
deed whole genome sequencing will likely be sufficiently
inexpensive (and potentially covered by health insurance),
eliminating the need for STGD-specific mutation
screening.
While important issues such as off-target findings and
variants of unknown significance remain highly controver-
sial in the field of genomic diagnostics, harnessing WES
technology to provide molecular diagnosis for a specific
subset of genes – essentially performing gene panels by
exome analysis – largely circumvents these issues. If parti-
cipants are properly consented, willing to participate, and
educated properly about the risks, benefits, and scope of
such testing, clinical molecular diagnosis and research can
and should be pursued simultaneously. With sufficient
sample sizes, a deeper understanding of locus heterogen-
eity and perhaps even modifier genes becomes possible.
This interplay between clinical testing and research should
provide better patient care and pave the way toward an
improved understanding of Stargardt Disease and macular
degeneration in general.
Conclusions
Genomic analysis is the most direct means to resolve the
clinical overlap of inherited early onset macular degener-
ation disorders. Based upon the striking level of success
in our most difficult to classify cases, clinical exome se-
quencing should be considered as a potential front line
diagnostic tool for retinal and macular dystrophies with
atypical presentations, as a follow-up after negative or
unclear results from initial screening by targetedmutation analysis, Additionally, WES may prove crucial
in ruling out rare mutations in genes that may confound
the determination of causality before proceeding to
gene-targeted therapies.Additional file
Additional file 1: Figure S1. Autofluorescence (A,B) and infrared (C,D)
imaging of participant STGD-01. Figure S2. Fundus photos of participant
STGD-02. Figure S3. Autofluorescence (AF) imaging and optical
coherence tomography (OCT) images for participant STGD-03. 50° AF
image of OD (A) and OS (B) shows geographic atrophy, discrete
autofluorescent flecks, and peripapillary sparing in both eyes. OCT of OD
(C) shows severe retinal edema. Figure S4. Autofluorescent imaging of
participant STGD-04. 30° AF image of OD (A) shows “stellate” pattern
dystrophy. Pattern less clear in OS (B). Figure S5. Autofluorescent
imaging of participant STGD-05. 50° AF imaging of both OD (A) and OS
(B) shows possible “stellate” pattern dystrophy. Figure S6. Red-free
fundus images of participant STGD-06. 30° fundus images of both OD (A)
and OS (B) show wide-spread geographic atrophy of the macula with
mild peripapillary sparing. Figure S7. Color fundus images of participant
STGD-07. 50° color fundus images from both OD (A) and OS (B) show
geographic atrophy with peripapillary sparing. Figure S8.
Autofluorescence and optical coherence tomography images for
participant STGD-08. 50° AF shows irregular geographic atrophy without
peripapillary sparing or autofluorescent flecks in both OD (A) and OS (B).
OCT shows an irregularly thickened contour of the retina in both OD (C)
and OS (D). Figure S9. Fundus photos of OD (A) and OS (B) for
participant STGD-08. Clear “horse-shoe” pattern of atrophy is observable
in both eyes.
Additional file 2: Table S1. Whole Exome Sequencing Details
Additional file 3: Figure S1. Autofluorescence (A,B) and infrared (C,D)
imaging of participant STGD-01.
Additional file 4: Figure S2. Fundus photos of participant STGD-02.
Additional file 5: Figure S3. Autofluorescence (AF) imaging and optical
coherence tomography (OCT) images for participant STGD-03. 50° AF
image of OD (A) and OS (B) shows geographic atrophy, discrete
autofluorescent flecks, and peripapillary sparing in both eyes. OCT of OD
(C) shows severe retinal edema.
Additional file 6: Figure S4. Autofluorescent imaging of participant
STGD-04. 30° AF image of OD (A) shows “stellate” pattern dystrophy.
Pattern less clear in OS (B).
Additional file 7: Figure S5. Autofluorescent imaging of participant
STGD-05. 50° AF imaging of both OD (A) and OS (B) shows possible
“stellate” pattern dystrophy.
Additional file 8: Figure S7. Color fundus images of participant STGD-
07. 50° color fundus images from both OD (A) and OS (B) show
geographic atrophy with peripapillary sparing.
Additional file 9: Figure S6. Red-free fundus images of participant
STGD-06. 30° fundus images of both OD (A) and OS (B) show wide-
spread geographic atrophy of the macula with mild peripapillary sparing.
Additional file 10: Figure S8. Autofluorescence and optical coherence
tomography images for participant STGD-08. 50° AF shows irregular
geographic atrophy without peripapillary sparing or autofluorescent
flecks in both OD (A) and OS (B). OCT shows an irregularly thickened
contour of the retina in both OD (C) and OS (D).
Additional file 11: Figure S9. Fundus photos of OD (A) and OS (B) for
participant STGD-08. Clear “horse-shoe” pattern of atrophy is observable
in both eyes.Abbreviations
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Mb: megabases.
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